REFERENCES
- Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst. 1990; 82: 4–6
- Kondo S, Asano M, Matsuo K. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim Biophys Acta 1994; 1221: 211–214
- Yamamoto Y, Toi M, Kondo S. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res 1996; 2: 821–826
- Kumar H, Heer K, Lee W P. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 1998; 4: 1279–1285
- Poon RTP, Ng IOL, Lau C. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg 2001; 233: 227–235
- Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non Hodgkin's lymphoma. Blood. 1997; 90: 3167–3172
- Bertolini F, Paolucci M, Peccatori F. Angiogenic growth factors and endostatin in non Hodgkin's lymphoma. Br J Haematol 1999; 106: 504–509
- Salven P, Orpana A, Teerenhovi L. Simulatneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single institution study of 200 patients. Blood 2000; 96: 3712–3718
- Mainou-Fowler T, Angus B, Miller S. Micro-vessel density and the expression of vascular endothelial growth factor (VEGF) and platelet–derived endothelial cell growth factor (PdEGF) in classical Hodgkin lymphoma (HL). Leuk Lymphoma 2006; 47: 223–230
- Tabone MD, Landman-Parker J, Arcil B. Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors?. Clin Cancer Res. 2001; 7: 538–543
- Pavlakovic H, Von Schutz V, Rossler J. Quantification of angiogenesis stimulators in children with solid malignancies. Int J Cancer 2001; 92: 736–760
- Ben Arush MW, Schenzer P, Maurice S. Serum vascular endothelial growth factor as a significant marker of treatment response in pediatric malignancies. Pediatr Hematol Oncol 2005; 22: 513–524
- Donaldson SS, Hudson M M, Lamborn R K. VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial. J Clin Oncol 2002; 20: 3081–3087
- Diehl V, Franklin J, Pfreundschuh M. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386–2395
- Doussis-Anagnostopoulou A I, Talks L K, Turley H. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease. J Pathol 2002; 197: 677–683
- Foss HD, Araujo I, Demel G. Expression of vascular endothelial growth factor in lymphomas and Castleman's disease. J Pathol 1997; 183: 44–50
- Agarwal B, Naresh KN. Re: Doussis-Anagnostopoulou, et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease. J Pathol. 2002;197:677–683. J Pathol 2003; 201: 334–335
- Giles F J, Vose JM, Do KA. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk Res. 2004; 28: 595–604